Novavax, Inc. Class Action Lawsuit - NVAX

The filed complaint alleges that Novavax, Inc. made materially false and/or misleading statements and/or failed to disclose that: On October 16, 2024, NVAX announced the Food and Drug Administration placed a clinical hold on the development of the company’s combination influenza and Covid-19 (CIC) shot and its stand-alone influenza vaccine. The hold was placed following a “serious adverse event of motor neuropathy” that occurred in a CIC Phase 2 trial participant outside the U.S., who received the vaccine in January of 2023. Following this news, NVAX’s stock price fell by $2.18 per share, or approximately 17% in premarket trading.

In order to be eligible to join the NVAX class action lawsuit, you must have incurred a loss on shares of Novavax, Inc. purchased during the class period listed above.